The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1547
May 21, 2018
View Complete Issue         Table of Contents 2019 
Clarithromycin in Patients with Coronary Artery Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Clarithromycin in Patients with Coronary Artery Disease
May 21, 2018 (Issue: 1547)
The FDA has warned that use of the macrolide antibiotic clarithromycin (Biaxin, and generics) may increase the risk of cardiovascular morbidity and mortality in patients with heart disease.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Clarithromycin in Patients with Coronary Artery Disease
Article code: 1547d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.